42 related articles for article (PubMed ID: 20435572)
1. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.
Arndt CA; Koshkina NV; Inwards CY; Hawkins DS; Krailo MD; Villaluna D; Anderson PM; Goorin AM; Blakely ML; Bernstein M; Bell SA; Ray K; Grendahl DC; Marina N; Kleinerman ES
Clin Cancer Res; 2010 Aug; 16(15):4024-30. PubMed ID: 20576718
[TBL] [Abstract][Full Text] [Related]
2. Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma.
Yong B; Tan P; Yin J; Zou C; Xie X; Wang J; Huang G; Wang Q; Shen J
World J Surg Oncol; 2012 Sep; 10():191. PubMed ID: 22985081
[TBL] [Abstract][Full Text] [Related]
3. Ginsenoside F1 attenuates pirarubicin-induced cardiotoxicity by modulating Nrf2 and AKT/Bcl-2 signaling pathways.
Zhang Y; Ma J; Liu S; Chen C; Li Q; Qin M; Ren L
J Ginseng Res; 2023 Jan; 47(1):106-116. PubMed ID: 36644383
[TBL] [Abstract][Full Text] [Related]
4. Identification of key biomarkers and functional pathways in osteosarcomas with lung metastasis: Evidence from bioinformatics analysis.
Liu D; Zhou R; Zhou A
Medicine (Baltimore); 2021 Feb; 100(6):e24471. PubMed ID: 33578541
[TBL] [Abstract][Full Text] [Related]
5. Analysis of changes in the expression of Notch1 and HES1 and the prognosis of osteosarcoma patients following surgery.
Fang L; Li B; Yu D; Wang B; Zhao T
Oncol Lett; 2020 Oct; 20(4):29. PubMed ID: 32774502
[TBL] [Abstract][Full Text] [Related]
6. Effect of DEC1 on the proliferation, adhesion, invasion and epithelial-mesenchymal transition of osteosarcoma cells.
Li S; Peng D; Yin ZQ; Zhu W; Hu XT; Liu CW
Exp Ther Med; 2020 Mar; 19(3):2360-2366. PubMed ID: 32104304
[TBL] [Abstract][Full Text] [Related]
7. Cold atmospheric plasma inhibits the growth of osteosarcoma cells by inducing apoptosis, independent of the device used.
Haralambiev L; Wien L; Gelbrich N; Lange J; Bakir S; Kramer A; Burchardt M; Ekkernkamp A; Gümbel D; Stope MB
Oncol Lett; 2020 Jan; 19(1):283-290. PubMed ID: 31897140
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of
Liu F; Zhang Q; Zhou D; Dong J
BMC Cancer; 2019 Apr; 19(1):323. PubMed ID: 30953476
[TBL] [Abstract][Full Text] [Related]
9. Cantharidin Inhibits Anti-Apoptotic Bcl-2 Family Proteins and Induces Apoptosis in Human Osteosarcoma Cell Lines MG-63 and MNNG/HOS via Mitochondria-Dependent Pathway.
Feng S; Zhu J; Xia K; Yu W; Wang Y; Wang J; Li F; Yang Z; Yang X; Liu B; Tao H; Liang C
Med Sci Monit; 2018 Sep; 24():6742-6749. PubMed ID: 30248086
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials.
Wang X; Zheng H; Shou T; Tang C; Miao K; Wang P
J Orthop Surg Res; 2017 Mar; 12(1):52. PubMed ID: 28356114
[TBL] [Abstract][Full Text] [Related]
11. Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment.
Li J; Yang Z; Li Y; Xia J; Li D; Li H; Ren M; Liao Y; Yu S; Chen Y; Yang Y; Zhang Y
Oncotarget; 2016 Jul; 7(28):44763-44778. PubMed ID: 27007056
[TBL] [Abstract][Full Text] [Related]
12. Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma.
Zheng S; Zhou S; Qiao G; Yang Q; Zhang Z; Lin F; Min D; Tang L; Li H; Sun Y; Zhao H; Shen Z; Yao Y
Am J Cancer Res; 2015; 5(1):411-22. PubMed ID: 25628949
[TBL] [Abstract][Full Text] [Related]
13. Follow-up of treated osteosarcoma patient.
Martins GE; Perez SV
Acta Ortop Bras; 2012; 20(4):235-9. PubMed ID: 24453610
[TBL] [Abstract][Full Text] [Related]
14. Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest.
Zheng SE; Xiong S; Lin F; Qiao GL; Feng T; Shen Z; Min DL; Zhang CL; Yao Y
Acta Pharmacol Sin; 2012 Jun; 33(6):832-8. PubMed ID: 22580740
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute.
Qi WX; He AN; Tang LN; Shen Z; Yao Y
Med Oncol; 2012 Sep; 29(3):2229-33. PubMed ID: 21748427
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis.
Zhao H; Yao Y; Wang Z; Lin F; Sun Y; Chen P
J Chemother; 2010 Apr; 22(2):119-24. PubMed ID: 20435572
[TBL] [Abstract][Full Text] [Related]
17. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
18. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
